Skip to main content
Premium Trial:

Request an Annual Quote

Bionano Genomics Posts Record Revenues in Q2

NEW YORK – Bionano Genomics reported a 72 percent year-over-year growth in second quarter revenues after the close of the market on Thursday.

For the quarter ended June 30, Bionano booked $6.7 million in revenues, a record for the company, up from $3.9 million in Q2 2021 and beating the average estimate of Wall Street analysts of $6.3 million.

Of those, $3.9 million were product revenues, up from $2.5 million in Q2 2021, and $2.8 million were service and other revenues, doubling from $1.4 million in the same period a year ago.

The total installed base of Saphyr systems at the end of the quarter was 196, with 20 systems shipped in the quarter, representing a 62 percent increase compared to Q2 2021.

The company also sold 3,394 nanochannel array flow cells during the quarter, a 24 percent increase over the year-ago quarter.

Bionano's net loss for the quarter swelled to $32.2 million, compared to a net loss of $18.8 million in Q2 2021. Bionano did not report earnings per share. Analysts, on average, had expected a net loss of $.09 per share.

The firm's R&D expenses almost tripled to $11.8 million from $4.1 million a year ago, while SG&A expenses grew 58 percent to $21.8 million from $13.8 million a year ago.

As of June 30, Bionano had $27.2 million in cash and cash equivalents and $160.2 million in investments.

The company maintained its full-year revenue guidance range of $24 million to $27 million.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.